New strategies for active immunotherapy with genetically engineered tumor cells

Research output: Contribution to journalArticle

Abstract

While previous tumor vaccine strategies have shown intriguing results, clearcut efficacy has been difficult to establish in human trials. Recently, newer approaches have been developed in animal systems that modify tumor cells genetically so that they express new antigens or secrete certain cytokines. Engineering tumor cells to secrete cytokines in a paracrine fashion can induce powerful local cytokine effects without producing significant systemic toxicity. In addition to local inflammation, this approach can alter the presentation of tumor antigen or activation of tumor antigen-specific T lymphocytes, resulting in systemic antitumor immunity.

Original languageEnglish (US)
Pages (from-to)619-623
Number of pages5
JournalCurrent Opinion in Immunology
Volume4
Issue number5
DOIs
StatePublished - 1992

Fingerprint

Active Immunotherapy
Neoplasm Antigens
Cytokines
Cell Engineering
Neoplasms
Cancer Vaccines
Immunity
Inflammation
T-Lymphocytes
Antigens

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

New strategies for active immunotherapy with genetically engineered tumor cells. / Pardoll, Andrew Mark.

In: Current Opinion in Immunology, Vol. 4, No. 5, 1992, p. 619-623.

Research output: Contribution to journalArticle

@article{a0bf76eea8ab4492870a47efbbc4ff17,
title = "New strategies for active immunotherapy with genetically engineered tumor cells",
abstract = "While previous tumor vaccine strategies have shown intriguing results, clearcut efficacy has been difficult to establish in human trials. Recently, newer approaches have been developed in animal systems that modify tumor cells genetically so that they express new antigens or secrete certain cytokines. Engineering tumor cells to secrete cytokines in a paracrine fashion can induce powerful local cytokine effects without producing significant systemic toxicity. In addition to local inflammation, this approach can alter the presentation of tumor antigen or activation of tumor antigen-specific T lymphocytes, resulting in systemic antitumor immunity.",
author = "Pardoll, {Andrew Mark}",
year = "1992",
doi = "10.1016/0952-7915(92)90037-F",
language = "English (US)",
volume = "4",
pages = "619--623",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - New strategies for active immunotherapy with genetically engineered tumor cells

AU - Pardoll, Andrew Mark

PY - 1992

Y1 - 1992

N2 - While previous tumor vaccine strategies have shown intriguing results, clearcut efficacy has been difficult to establish in human trials. Recently, newer approaches have been developed in animal systems that modify tumor cells genetically so that they express new antigens or secrete certain cytokines. Engineering tumor cells to secrete cytokines in a paracrine fashion can induce powerful local cytokine effects without producing significant systemic toxicity. In addition to local inflammation, this approach can alter the presentation of tumor antigen or activation of tumor antigen-specific T lymphocytes, resulting in systemic antitumor immunity.

AB - While previous tumor vaccine strategies have shown intriguing results, clearcut efficacy has been difficult to establish in human trials. Recently, newer approaches have been developed in animal systems that modify tumor cells genetically so that they express new antigens or secrete certain cytokines. Engineering tumor cells to secrete cytokines in a paracrine fashion can induce powerful local cytokine effects without producing significant systemic toxicity. In addition to local inflammation, this approach can alter the presentation of tumor antigen or activation of tumor antigen-specific T lymphocytes, resulting in systemic antitumor immunity.

UR - http://www.scopus.com/inward/record.url?scp=0026730155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026730155&partnerID=8YFLogxK

U2 - 10.1016/0952-7915(92)90037-F

DO - 10.1016/0952-7915(92)90037-F

M3 - Article

VL - 4

SP - 619

EP - 623

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 5

ER -